P68 Cost-Effectiveness of Ofatumumab in Comparison with Teriflunomide for Relapsing Multiple Sclerosis Treatment in China: From Both Healthcare System and Societal Perspectives
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.087
https://www.valueinhealthjournal.com/article/S1098-3015(22)00288-1/fulltext
Title :
P68 Cost-Effectiveness of Ofatumumab in Comparison with Teriflunomide for Relapsing Multiple Sclerosis Treatment in China: From Both Healthcare System and Societal Perspectives
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00288-1&doi=10.1016/j.jval.2022.04.087
First page :
Section Title :
Open access? :
No
Section Order :
10074